


PHARMACEUTICAL 2022

MEI Pharma Inc. Rank 357 of 466









PHARMACEUTICAL 2022

MEI Pharma Inc. Rank 357 of 466



The relative strengths and weaknesses of MEI Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEI Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 26% points. The greatest weakness of MEI Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 123% points.

The company's Economic Capital Ratio, given in the ranking table, is 13%, being 65% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	164,817
Cost of Goods Sold	1,408
Intangible Assets	0
Liabilities, Current	30,294
Liabilities, Non-Current	7,370
Other Assets	7,774
Other Compr. Net Income	0
Other Expenses	8.0
Other Liabilities	95,072
Other Net Income	19,118
Other Revenues	25,535
Property and Equipment	1,507
Research and Development	69,398
Selling, General and Administrative Expense	24,414

Output Variable	Value in 1000 USD
Assets	174,098
Liabilities	132,736
Expenses	95,228
Revenues	25,535
Stockholders Equity	41,362
Net Income	-50,575
Comprehensive Net Income	-50,575
Economic Capital Ratio	13%

